Ubs Group Ag I Mab Put Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IMAB
# of Institutions
44Shares Held
16.4MCall Options Held
3KPut Options Held
1.9K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$8.98 Million0.3% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$5.42 Million3.04% of portfolio
-
Boothbay Fund Management, LLC New York, NY1.38MShares$1.79 Million0.07% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny577KShares$749,5800.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$736,6450.0% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $108M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...